NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.68 +0.66 (+0.85%) GOLD FUTURES
2,392.60 +32.70 (+1.39%) DOW
39,836.27 +278.16 (+0.70%) Bitcoin GBP
51,591.08 +3,263.90 (+6.75%)
NBIX May 2024 100.000 put
| Previous close | 1.4000 |
| Open | 1.4000 |
| Bid | 0.7500 |
| Ask | 1.1000 |
| Strike | 100.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.4000 - 1.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 60 |
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented a
Investor's Business DailyHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
- PR Newswire
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH.
